MEDIA COVERAGE

Benzinga

- Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab

BioSpace

- KEYTRUDA® Plus LENVIMA® Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study
- Merck and Eisai's Keytruda-Lenvima Combo Dazzles in Endometrial Cancer Trial
- Leap Therapeutics Presents DKN-01 Clinical Data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer

Business Wire

- Clovis Oncology's Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation

Cancer Network

- ARIEL4 Trial Confirms PFS Benefit of Rucaparib in BRCA+ Relapsed Ovarian Cancer
- Visible Residual Disease Following Interval Debulking in Ovarian Cancer Is Associated With Positive Outcomes With Niraparib
- Pembrolizumab/Lenvatinib Combo Shows Survival Benefit in Advanced Endometrial Cancer
- Ursula A. Matulonis, MD, on Various Advancements in Gynecologic Cancers Presented at SGO 2021
- Phase 2 ENPAC Trial Shows Feasibility of Enzalutamide Triplet in Endometrioid Endometrial Cancer
- For Ovarian Cancer Treated With Olaparib/Bevacizumab, CA-125 Shows Promise for Identifying Disease Progression
- BJ Rimel, MD, Discusses Biggest Takeaways from 2021 SGO Annual Meeting

Healio

- Survey: Most female gynecologic oncologists have faced workplace bullying, harassment
- Top in hem/onc: Harassment among female gynecologic oncologists, Keytruda approval

HealthDay

- Drug Boosts Survival for Women With Advanced Ovarian Cancer
- An IUD Could Ward Off Endometrial Cancer in Women at Risk

Journal of Clinical Pathways

- Pembrolizumab and Lenvatinib Use for Endometrial Cancer in Clinical Practice
- Medicare Reimbursement Trends for Gynecologic and Urologic Procedures
MEDIA COVERAGE

MDEdge

- Gynecologic cancer patients at risk of insurance loss, ‘catastrophic’ costs

MedPage Today

- PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancer
- Is MIS Viable for Interval Debulking in Ovarian Cancer?
- Hormonal IUD Shows Promise in Early Endometrial Cancer
- Androgen Receptor Inhibitor Active in Endometrial Cancer
- Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer
- Triage System Gets High Marks for Ovarian Cancer Debulking Surgery

Pharmacy Times

- Hormonal IUD Shows Promise as an Effective Treatment for Early Endometrial Cancer or Precancer
- Study Demonstrates Promising Results for GEN-1 in Advanced Ovarian Cancer
- Study Finds Risk of Death Due to COVID-19 Not Raised by Recent Chemotherapy, Immunotherapy for Gynecologic Cancer
- Monotherapy Demonstrates Promising Clinical Activity in Endometrial Cancer
- Pembrolizumab Plus Lenvatinib Demonstrates Improved Overall Survival in Treatment of Advanced Endometrial Cancer
- Olaparib as Maintenance Drug Reduces Disease Progression for Advanced Ovarian Cancer

Targeted Oncology

- The Rationale of Maintenance With Durvalumab With or Without Olaparib in Patients With Endometrial Cancer

The ASCO Post

- Survey Reveals Workplace Bullying, Gender Discrimination, and Microaggressions Not Uncommon for Women Gynecologic Oncologists
- PARP Inhibition Shows Efficacy in Ovarian Cancer Regardless of Number of Prior Lines of Chemotherapy, BRCA Mutation Status
- Pembrolizumab/Lenvatinib May Improve Survival in Advanced Endometrial Cancer

Yahoo

- Poster on Celsion Corporation’s Phase I/II OVATION 2 Study Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer